NCT04805736View on ClinicalTrials.gov

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Breast Cancer
Interventions
PROCEDURE

Microwave Ablation

Image-guided microwave ablation 7-10 days prior to surgery

DRUG

Camrelizumab

Camrelizumab 200 mg was given a few days after microwave ablation

PROCEDURE

Breast Surgery

Standard of care breast conserving surgery or radical mastectmoy

Trial Locations (1)

Unknown

the First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT04805736 - Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer | Biotech Hunter | Biotech Hunter